Results of the HYBRID trial presented

October 31, 2013

A hybrid approach to treating coronary artery disease that involves a "hybrid procedure" combining a minimally invasive bypass surgery with percutaneous coronary intervention (PCI) was found to be feasible and safe in a clinical trial. This is the first randomized study of the technique. These findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Hybrid coronary artery revascularization (HCR) as studied within this trial combined a minimally invasive left internal mammary artery bypass grafting to the left anterior descending artery (LAD) with (PCI) with drug-eluting stent (DES) implantation to other coronary arteries. Due to the lack of data from large, prospective randomized trials comparing HCR with standard surgical revascularization, HYBRID was designed as a feasibility study to assess the safety and efficacy of HCR in patients with multi-vessel referred for standard grafting (CABG).

Two hundred consecutive patients, with angiographically confirmed multi-vessel disease (CAD) involving the LAD and a critical (>70%) lesion in at least one major epicardial vessel (except LAD) amenable to both PCI and CABG, were randomized in a 1:1 fashion to HCR or standard surgical revascularization.

The primary objectives of this trial were to investigate the feasibility and safety of HCR. The feasibility assessment was defined both as the percentage of patients in the hybrid group that had a complete HCR procedure according to the study protocol and a percentage that had to be converted to standard CABG. The safety endpoint was the occurrence of MACE (major adverse cardiac events) such as death, myocardial infarction, stroke, repeat revascularization, major bleeding within the 12 month period after randomization. In the trial, 93.9 percent of the patients in the hybrid group had the completed HCR procedure and 6.1 percent were converted to CABG.

At one year, 92.2 percent of the CABG group and 89.8 percent of the hybrid group were free from MACE. No strokes were reported in either group. The rate of death was 2.9 percent in the CABG group and 2.0 percent in the HCR group.

"This first randomized pilot study on hybrid coronary revascularization shows promising feasibility and safety results supporting the idea of hybrid coronary revascularization in patients with multi-vessel disease," said Michal Hawranek, MD, PhD, on behalf of the investigation team at the Silesian Center for Heart Disease in Zabrze, Poland.

Explore further: Results of the FREEDOM sub study reported

Related Stories

Results of the FREEDOM sub study reported

October 31, 2013
According to a recent study of diabetic patients who underwent revascularization for multi-vessel coronary artery disease (CAD), patients treated with insulin experienced more major adverse cardiovascular events after revascularization ...

Results of the SMART-CASE trial presented

October 30, 2013
A new study shows that a conservative approach to revascularization for patients with intermediate coronary lesions determined by angiographic diameter stenosis is safe and non-inferior to an aggressive approach. Findings ...

Results of the ADVISE II trial presented

October 30, 2013
A new study supports the use of instantaneous wave-free ratio (iFR), to simplify assessment and determine the severity of coronary artery disease. ADVISE II findings were presented today at the 25th annual Transcatheter Cardiovascular ...

For patients with diabetes, angioplasty and bypass surgery lead to similar long-term benefits for quality of life

October 15, 2013
For patients with diabetes and coronary artery disease in more than one artery, treatment with coronary artery bypass graft surgery provided slightly better health status and quality of life between 6 months and 2 years than ...

Results of the SORT-OUT VI trial presented

October 30, 2013
A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible ...

New study compares provisional and two-stent strategies for coronary bifurcation lesions

October 30, 2013
A new clinical trial shows that a two-stent technique for treatment of bifurcation lesions with a large stenotic side branch was not associated with significant improved outcomes compared to a provisional stenting approach. ...

Recommended for you

Some cancer therapies may provide a new way to treat high blood pressure

November 20, 2017
Drugs designed to halt cancer growth may offer a new way to control high blood pressure (hypertension), say Georgetown University Medical Center investigators. The finding could offer a real advance in hypertension treatment ...

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

Raising 'good' cholesterol fails to protect against heart disease

November 16, 2017
Raising so-called 'good' cholesterol by blocking a key protein involved in its metabolism does not protect against heart disease or stroke, according to a large genetic study of 150,000 Chinese adults published in the journal ...

Popular e-cigarette liquid flavorings may change, damage heart muscle cells

November 16, 2017
Chemicals used to make some popular e-cigarette liquid flavorings—including cinnamon, clove, citrus and floral—may cause changes or damage to heart muscle cells, new research indicates.

Possible use for botulinum toxin to treat atrial fibrillation

November 16, 2017
From temporarily softening wrinkles to easing migraines, botulinum toxin has become a versatile medical remedy because of its ability to block nerve signals that can become bothersome or risky.

New model estimates odds of events that trigger sudden cardiac death

November 16, 2017
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death. The model, developed by Mark Walker and colleagues from Johns ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.